Loading company…
SixPeaks Bio develops therapies intended to support weight loss while preserving muscle mass.
Founded in 2022 and based in Basel, Switzerland, SixPeaks Bio develops medicines for weight management and metabolic health. Its pipeline includes a dual-specific antibody targeting activin type IIA and B receptors, designed to preserve skeletal muscle during weight loss and complement GLP-1 therapies. Versant Ventures led its USD 30 million Series A round in May 2024, with AstraZenec participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in